CV
CapsoVision, Inc. NASDAQ$7.07
Mkt Cap $352.4M
52w Low $3.43
30.5% of range
52w High $15.37
50d MA $6.14
200d MA $5.81
P/E (TTM)
-7.3x
EV/EBITDA
-104.8x
P/B
138.9x
Debt/Equity
0.1x
ROE
-190.9%
P/FCF
-114.4x
RSI (14)
—
ATR (14)
—
Beta
-4.12
50d MA
$6.14
200d MA
$5.81
Avg Volume
314.5K
About
Medical‑technology company developing advanced capsule endoscopy systems (CapsoCam Plus, CapsoCam Colon) and AI-enabled imaging platforms for gastrointestinal diagnostics
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | -0.17 | -0.15 | +8.8% | 7.53 | -9.2% | -0.3% | -4.9% | -3.2% | -11.7% | -1.2% | — |
| Nov 13, 2025 | AMC | -0.14 | -0.17 | -21.4% | 5.67 | -8.1% | -9.7% | -6.9% | -3.0% | -6.0% | -6.0% | — |
| Aug 14, 2025 | AMC | -0.11 | -2.02 | -1736.4% | 4.02 | -2.2% | -4.2% | -0.5% | -3.2% | -2.0% | -1.0% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 27 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $7.53 | $6.84 | -9.2% | -0.3% | -4.9% | -3.2% | -11.7% | -1.2% |
| Dec 31 | Benchmark | Maintains | Speculative Buy → Speculative Buy | — | $12.39 | $12.48 | +0.7% | -13.7% | -17.4% | -31.5% | -35.8% | -39.2% |
Recent Filings
8-K
Unknown — 8-K Filing
CV's 13% YoY revenue growth to $3.9M signals commercialization progress, but investors should monitor whether this early-stage medtech can reach profitability before cash depletion threatens viability.
Mar 26
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Equity Issuance
CV's equity issuance dilutes existing shareholders' ownership and may pressure the stock price, though the capital raised likely funds operations or strategic initiatives.
Mar 20
8-K
Unknown — 8-K Filing
Cogent Inc's development costs for Canon partnership rose $1 million due to enhanced specifications, reducing near-term profitability but potentially positioning the product for stronger market acceptance and revenue generation.
Mar 13
Data updated apr 25, 2026 4:01am
· Source: massive.com